Only a small number of patients with aggressive B-cell lymphoma participates in clinical trials, particularly elderly patients are underrepresented. Therefore, we studied data of the population-based nationwide Netherlands Cancer Registry to determine trends in incidence, treatment and survival in an unselected patient population.
Introduction
Randomized clinical trials of aggressive non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and Burkitt lymphoma (BL) show considerable improvement in clinical outcome over the last two decades. First, the introduction in 1997 of the monoclonal antibody targeting CD20, rituximab, increased overall survival (OS). [1] [2] [3] [4] Second, the introduction of more intensive therapy in first-line treatment, including autologous stem cell transplantation (ASCT), improved OS of MCL en BL. [5] [6] [7] [8] [9] However, only a small selection taken from the entire population typically participates in randomized clinical trials. Particularly patients with comorbidities and age-related organ dysfunction are underrepresented in clinical trials. 10 Moreover, patients aged 80 years or older are often excluded from trials. 3, 11 This situation highlights the importance of populationbased registries that provide the opportunity to determine whether new treatment options are implemented and whether this is beneficial in an unselected patient population, including elderly patients or patients with marked comorbidity.
Several existing population-based registries on the clinical outcome in aggressive B-cell lymphoma show an improvement in survival. [12] [13] [14] However, this is the first large populationbased study with separate analyses of specific pathological subtypes of aggressive B-cell lymphoma in different age groups, with regard to incidence and survival over time.
Methods

Study population and data collection
The As the survival pattern (a high number of deaths in the first year after diagnosis) of unspecified NHL was roughly the same as for DLBCL or BL, unspecified NHL (decreasing from 18% in 1989-1993 to 6% in 2005-2010) was considered as aggressive lymphoma and classified as DLBCL (as 84% of aggressive lymphoma is DLBCL) for the incidence analyses.
This was done to minimize the effect of changes in classification on outcome of trends analyses of incidence. For the survival analyses we excluded the unspecified cases.
Year of diagnosis was divided into four periods for DLBCL and BL: 1989 -1993 , 1994 -1998 , 1999 
Statistical analyses
Annual incidence rates according to gender for the period 1989-2010 were calculated per 100.000 person-years, using the annual mid-year population size as obtained from Statistics
Netherlands. Rates were age standardized to the European standard population (ASR).
Incidence rates were also calculated per age group. Trends in incidence were evaluated by calculating the estimated annual percentage change (EAPC) and the corresponding 95% confidence interval (95%CI).
Relative survival (RS), which can be interpreted as disease-specific survival within a cancer patient population (independent of the cause of death), was estimated as ratio of the observed survival of cancer patients and the expected survival of a comparable age-and sex-matched group of the general population.
For a comparison with results from recent clinical studies we also calculated OS. For each There was a strong male predominance for MCL and BL, 74% and 66%, respectively, which was not observed in DLBCL patients (53%). Stage IV disease was more pronounced in MCL and BL (70 and 55% respectively), versus 30% in DLBCL.
Trends in incidence
Age-standardized incidence (ASR) per 100,000 person-years remained stable for DLBCL 
Trends in first-line treatment
DLBCL
The majority of patients with DLBCL (56%) received "chemotherapy alone", in particular for stage II, III and IV. The percentage of patients with stage I that received "radiotherapy alone" decreased over time (from 33% to 10%), whereas the percentage of patients that received combination "chemotherapy plus radiotherapy" increased (from 18% to 37%) (figure 3A).
A considerable proportion of elderly patients did not receive any treatment (17% in patients 65-74 and 36% in patients 
Trends in survival
In the first ten years of the study period (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) . However, these data were not statistically significant. Gender did not significantly affect these results. Table 2 presents a comparison of OS from our study with recent clinical trials, with the same age range and same diagnosis as patients in the equivalent trial. Our study showed inferior survival rates for patients with DLBCL, MCL and BL, even when untreated patients were excluded.
Discussion
Our population-based registry showed similar incidence rates to those found in other studies conducted in Europe, in particular the similar increase in incidence of male patients with MCL and BL. [15] [16] [17] The causes for male predominance in MCL and BL are still unknown. [18] [19] [20] Furthermore, our study showed a pronounced improvement in survival for patients with aggressive B-cell lymphoma, particularly during the last decade. Although the improvement in survival was observed independent of age, the outcome was significantly inferior in the elderly patients, especially in patients over 75 years of age. Compared with previous population-based studies in Europe and the United States, our study showed similar RS for patients with aggressive B-cell lymphoma. respectively. 33 Furthermore, comorbidity has been found to be related to age. In the study of Janssen-Heijnen, 79% of patients aged >60 years diagnosed with NHL had serious comorbidity, in contrast to only 48% for patients <60 years.
comorbidity the percentage of patients receiving chemotherapy declined, especially among elderly patients. 35 This is supported by the significantly higher proportion of elderly patients in our study compared to clinical trials, with a mean age of 66 years in our study versus 61 years in the study of Cunningham. 36 A considerable number of the elderly patients in our study did not receive any treatment and consequently they had a low survival rate. However, even after correcting for non-treatment the survival remains inferior when compared with clinical trials.
Differences in therapy could be a second reason. For example, rituximab came into use in the USA in 1997 and in Europe in 2000, albeit not simultaneously in all countries. 37, 38 This is reflected by the consistently observed higher OS in the rituximab treated patients in the randomized clinical trials as described in Table 2 . Besides, in general a delay in the introduction of new agents is observed in the elderly population with comorbidity. For example, the proportion elderly patients with MCL in our study received less treatment with rituximab than younger patients.
A further explanation is that in general elderly patients did not receive intensive chemotherapy combined with an autologous stem cell transplantation, whereas a high percentage of the younger patients did. This is established in our study in particular for the patients with MCL: patients <65 years were treated with a stem cell transplantation in 50% of the cases in contrast to 1% in patients >65 years.
Several studies have reported that elderly patients, aged up to 80 years, are able to tolerate full-dose R-CHOP regimens. 3, 5, 36 Although approximately one third of the cases of NHL occur in patients older than 75 years, few data are available concerning the optimal treatment in this age group. It has been assumed that many older patients are too frail to receive standard therapy. 10, 39 Peyrade showed in very elderly patients aged over 80 years, that addition of rituximab to 50%-reduced CHOP seems to be a good compromise between toxicity and efficacy, with a 2-year OS of 59%. 40 Although precise data on the dose of therapy is lacking, also in our study good results were observed for elderly patients receiving treatment as well, Third, despite the rather clinical nature of the Dutch cancer registries, lack of detailed information regarding exact treatments, comorbidities and dose adherence in our populationbased registry limited the possibility to explore and clarify specific reasons for the observed changes in survival.
In conclusion, in the Netherlands, survival for newly diagnosed patients with aggressive Bcell lymphoma has increased over time, particularly in patients aged < 65 years. However, even though survival of elderly patients was inferior in comparison with survival of younger patients, a similar increase in survival occurred when treatment was initiated.
The main contributors for the improvement in survival in our study and clinical trials appear to be rituximab therapy, 1-4,37,41-43 autologous stem cell transplantation and the use of more intensive chemotherapy.
5-9,44-46
The therapeutic goal in treating elderly NHL patients must be maintaining a balance between effective therapy and treatment toxicity. As patients over 65 years constitute around twothirds of all patients with aggressive lymphoma, clinical trials for elderly 'frail' patients with no barrier for comorbidity, are needed to determine appropriate therapy for these patients.
Comprehensive geriatric assessment (CGA) could be used for additional information. 47, 48 Since more detailed information regarding exact treatments, dose adherence and comorbidities is important for a better understanding of the treatment and outcome of patients with haematological malignancies, an extensive registry was initiated in the Netherlands, supplementary to the cancer registry. This PHAROS registry (Population-based
Haematological Registry for Observational Studies) is expected to supply more detailed data in the near future. 
